Creso Pharma Limited (COPHF) Comparison with companies in other sectors?

Creso Pharma Limited has a share price of 1.13B. You can analyze Creso Pharma Limited (COPHF) competitors across different market sectors through stock heatmaps.

What are COPHF's NET and operating margins?

Creso Pharma Limited (COPHF) operating margin is around -0.88, and net profit margin is approximately -2.77 as of the latest reports.

In what way does COPHF's earnings per share (EPS) trend reflect its financial momentum?

Creso Pharma Limited (COPHF) EPS is -5.08 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Creso Pharma Limited is -0.02, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Creso Pharma Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Creso Pharma Limited like P/E which is 0.00, P/B which is 0.00, and PEG which is 0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Creso Pharma Limited

COPHF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$0.12

$0.00(0.00%)

Fundamental Analysis of Creso Pharma Limited (COPHF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-5.08

P/E Ratio

-0.02

ROE

-5.75%

Net Margin

-2.77%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$131.72M

Shares OutstandingTotal number of shares issued

$1.13B

Book Value/ShareNet worth per share

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-5.08

Net MarginNet income as percentage of revenue

-277.18%

Operating MarginOperating income as percentage of revenue

-88.16%

ROEReturn on shareholders' equity

-575.19%

ROAReturn on total assets

-275.39%

ROCEReturn on capital employed

419.73%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

FCF YieldFree cash flow as percentage of market cap

-4.21%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for COPHFFinancial Ratios Analysis details for COPHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for COPHFSector Benchmarking details for COPHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Creso Pharma Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Creso Pharma Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Creso Pharma Limited's unique business strengths and challenges.

Key Financial Metrics for Creso Pharma Limited

For Creso Pharma Limited, essential financial indicators include EPS -5.08, PE -0.02, and ROE -5.75. These key ratios reveal insights into Creso Pharma Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Creso Pharma Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Creso Pharma Limited

Metrics like Net Margin -277.18% and ROA -275.39% shed light on how well Creso Pharma Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Creso Pharma Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Creso Pharma Limited

Using ratios such as P/B Ratio - and PEG Ratio -, investors can assess whether Creso Pharma Limited is appropriately valued based on its financials and growth potential. These figures, combined with Creso Pharma Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Creso Pharma Limited

Financial health indicators, such as Debt/Equity Ratio -2.38 and Cash Flow -, provide a snapshot of Creso Pharma Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Creso Pharma Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Creso Pharma Limited

Investing in Creso Pharma Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Creso Pharma Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;